pCPA Reaches Pricing Deal for Winrevair™, Bringing Breakthrough Rare Disease Treatment Closer to Patients

VANCOUVER, BC (Nov. 20, 2025)

The Pulmonary Hypertension Association of Canada (PHA Canada) is delighted that the pan-Canadian Pharmaceutical Alliance (pCPA) has successfully concluded negotiations on behalf of public drug payers for the price of Winrevair™ (sotatercept), a breakthrough treatment option for pulmonary arterial hypertension (PAH), a serious, complex, and potentially fatal rare lung disease.

“This is great news for PAH patients. There is still a lot of work to do before we can get sotatercept into people’s arms across Canada, but this is an important step toward significantly improving care for PAH patients in this country,” says respirologist Dr. Mitesh Thakrar, a pulmonary hypertension expert in Calgary, Alberta and board Director at PHA Canada.

Winrevair (sotatercept) is a new medication class that improves people's functionality and reduces mortality risk by 84%. Winrevair is the first disease-modifying treatment for PAH. It has been demonstrated in clinical trials to be effective across a range of patients, including those newly diagnosed, those with comorbidities, and the sickest patients facing no other treatment options.

“I reached a point where there were no additional medicinal options left for me. My next treatment would have been a double lung transplant. Then I was given early access to sotatercept, and it changed everything. My energy improved, my breathing became easier, and my heart isn’t under so much strain. Sotatercept is giving me back the quality of life I didn’t think was possible anymore. It’s allowed me to think of my future with optimism instead of fear. We need to make sure that everyone who needs access to this medication has it,” says Brooke Paulin, from Mississauga, Ontario, who was diagnosed with PAH in 2014 at the age of 24.

PHA Canada and patient advocates nationwide have been calling on the provinces and territories to finalize pricing negotiations for sotatercept for over a year. Sotatercept received priority review from Health Canada and was approved in August 2024; however, the pCPA didn’t begin negotiations on behalf of the public drug payers until April 2025. PAH patients cannot continue to wait. Now that pCPA negotiations have successfully concluded, PHA Canada urges all provinces and territories to provide immediate public coverage of sotatercept and ensure equitable access for Canadian PAH patients who need this life-changing medication. 

About the Pulmonary Hypertension Association of Canada (PHA Canada) 

PHA Canada is a federally registered charity whose mission is to empower the Canadian pulmonary hypertension community through support, education, advocacy, awareness, and research. PHA Canada was established in 2008 by patients, caregivers, and healthcare professionals to work together to better the lives of Canadians affected by pulmonary hypertension and represent a united national pulmonary hypertension community.

For more information about the Pulmonary Hypertension Association of Canada, visit www.phacanada.ca.

About pulmonary arterial hypertension (PAH)

PAH is a rare type of PH that is specifically due to the narrowing of the pulmonary arteries (blood vessels) that carry blood to the lungs. The exact cause of PAH is not well understood. Narrowing of the pulmonary arteries in PAH is due to the multiplication and growth of cells in the walls of the pulmonary arteries, as well as the formation of scar tissue within the pulmonary arteries. Ongoing research has identified numerous biologic abnormalities in PAH, including genetic, protein, and small molecular abnormalities within the body.

Learn more about pulmonary arterial hypertension.

— END —

Media Contact:

Jeremy Durand

Manager, Marketing & Communications

Pulmonary Hypertension Association of Canada

jdurand@phacanada.ca